Search Results

Baxter Reports Second-Quarter 2022 Results

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2022.

Supporting Patients in Extraordinary Times

Continuous renal replacement therapy (CRRT) is the cornerstone of treatment in patients with severe acute kidney injury (AKI), one of many complications affecting COVID-19 patients. Throughout the pandemic, Baxter has been doing all it can to help meet the increased need for CRRT products, including filter sets used to remove fluid and uremic toxins from the patient’s blood during CRRT before the cleaned blood is returned to the body.

Baxter Highlights Business Strategies and Innovation at 2022 Investor Conference

Baxter International Inc. (NYSE:BAX), a global medtech leader, will showcase its ongoing trajectory of transformation and growth at its 2022 Investor Conference, being held today in Glenview, Ill. The company's executive leadership team will highlight Baxter’s strategy to continue creating compelling value for patients, clinicians and investors through leading-edge innovation, market expansion, operational efficiency and other vital growth levers.

Baxter Reports First-Quarter 2022 Results

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2022.

Baxter Announces U.S. FDA Clearance of ST Set Used to Help Treat Acute Kidney Injury Patients in the Hospital

Baxter International Inc. (NYSE:BAX), a global leader in acute care, today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance of the company’s ST Set used in continuous renal replacement therapy (CRRT). The ST Set is a pre-connected, disposable, extracorporeal (outside the body) circuit that provides blood purification through a semipermeable membrane to be used with the PrisMax or Prismaflex control units (monitors).

Baxter Presents Data Indicating Sharesource Increases Patients’ Time on Home Dialysis by More Than Three Months

Baxter International Inc. (NYSE:BAX), a global innovator in kidney care, announced today new data indicating the use of Baxter’s Sharesource remote patient management platform with an automated peritoneal dialysis (APD) cycler may improve the clinical effectiveness of home kidney patients care by extending their time on therapy by 3.4 months.

Baxter Reports Fourth-Quarter and Full-Year 2021 Results

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2021, and provided its financial guidance for full-year and first-quarter 2022. Fourth-quarter and full-year 2021 results reflect 19 days of contribution from Hillrom Holdings, Inc. (Hillrom) subsequent to Baxter’s acquisition of the company on Dec. 13, 2021.

Powered by a Pursuit for Patient Care

Working in an inclusive and diverse environment has provided Angela Rivera with opportunities to learn, grow and share knowledge. The global medical leader for Renal Therapy Services (RTS) shares insights from her wide-ranging career experiences at Baxter.  

Baxter Declares Quarterly Dividend

Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that its Board of Directors has declared a quarterly cash dividend of $0.28 per share of common stock. The dividend is payable on January 3, 2022, to shareholders of record as of December 3, 2021. The indicated annual dividend rate is $1.12 per share of common stock.  About Baxter

Baxter Named to Dow Jones Sustainability Indices in Recognition of Continued Commitment to Corporate Responsibility

Baxter International Inc. (NYSE: BAX), a leading global medical products company, today announced it was again named to the S&P's Dow Jones Sustainability Indices (DJSI), including both DJSI World and DJSI North America. Baxter has proudly been included in the DJSI World and DJSI North America each year since they launched, in 1999 and 2005, respectively.